ArticleFrontiers in medicine2026
Evaluation of neutrophil activation in autoimmune kidney diseases using blood heparin-binding protein: a pilot study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, there is limited understanding about the activation of neutrophils in autoimmune kidney diseases. Heparin-binding protein (HBP) is a protein in neutrophil granules and has been widely used as a marker for infectious diseases. This study aims to explore the use of blood HBP to evaluate neutrophil activation in autoimmune kidney diseases. Methods: A total of 70 patients diagnosed with autoimmune kidney diseases were enrolled, including 20 with anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV), 17 with membranous nephropathy (MN), 17 with IgA nephropathy (IgAN), and 16 with minimal change disease (MCD)/focal segmental glomerulosclerosis (FSGS). The control group consisted of 18 patients with sepsis, 20 patients on maintenance hemodialysis, and 20 healthy volunteers. Clinical and laboratory indicators were collected, and the blood HBP were measured. Results: The blood HBP were significantly elevated in all kinds of autoimmune kidney disease, with the highest levels in AAV and the lowest in MCD/FSGS. Unlike blood NGAL, blood HBP was not affected by estimated glomerular filtration rate (eGFR). Blood HBP was independently correlated with blood neutrophil counts, and its sensitivity was higher than that of blood NGAL, neutrophil counts, and C-reactive protein. In AAV, blood HBP was associated with hematuria, and its levels significantly decreased after remission. In MN and MCD/FSGS, elevated HBP was associated with higher levels of proteinuria. There was a positive correlation between blood HBP and urine HBP in patients with autoimmune kidney diseases. Conclusion: Blood HBP is a valuable and eGFR-independent marker of neutrophil activation. This study preliminarily reveals that neutrophil activation is widespread in various autoimmune kidney diseases and may be involved in the pathogenesis of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.